|1.||Mologni, Luca: 1 article (01/2012)|
|2.||Brussolo, Stefania: 1 article (01/2012)|
|3.||Ceccon, Monica: 1 article (01/2012)|
|4.||Gambacorti-Passerini, Carlo: 1 article (01/2012)|
|5.||Schlösser, Axel: 1 article (04/2010)|
|6.||Minke, Katharina: 1 article (04/2010)|
|7.||Staib, Peter Anton: 1 article (04/2010)|
|8.||Schmitt, Esther Katharina: 1 article (04/2010)|
|9.||Hallek, Michael: 1 article (04/2010)|
|10.||Gandhirajan, Rajesh Kumar: 1 article (04/2010)|
05/01/2007 - "In xenograft models of human MM, PKF115-584 inhibits tumor growth and prolongs survival. "
04/01/2010 - "In vivo studies exhibited tumor inhibition of 69% with CGP049090 and 57% with PKF115-584 when compared with vehicle-treated controls, and the intervention was well tolerated. "
08/01/2008 - "The objective of the study was to investigate the effect of the small-molecule inhibitor of the T cell factor (Tcf)/beta-catenin complex PKF115-584 on beta-catenin-dependent transcription and proliferation of H295R adrenocortical tumor cells, which harbor mutations in CTNNB1 as well as the TP53 tumor suppressor gene. "
|3.||Colonic Neoplasms (Colon Cancer)
01/01/2012 - "We show here that the β-catenin inhibitors PKF115-584 and pyrvinium pamoate block β-catenin-dependent transcriptional activity and synergize with the KRAS inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS, salirasib) in colon cancer cells driven by Wnt and KRAS oncogenic signals, but not in cells carrying BRAF mutations. "
|1.||Heterologous Transplantation (Xenotransplantation)